Development of a risk prediction tool for patients with locally advanced and recurrent rectal cancer undergoing pelvic exenteration: protocol for a mixed-methods study
Name:
37648387.pdf
Size:
641.0Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, AustraliaIssue Date
2023
Metadata
Show full item recordAbstract
Introduction: Pelvic exenteration (PE) surgery represents the only potentially curative treatment option for patients with locally advanced or recurrent rectal cancer (LARRC). Given the potential morbidity, whether or not PE should be recommended for an individual patient presents a major decisional conflict. This study aims to identify the outcomes of PE for which there is consensus among patients, carers and clinicians regarding their importance in guiding treatment decision-making, and to develop a risk prediction tool which predicts these outcomes. Methods and analysis: This study will be conducted at a specialist PE centre, and employ a mixed-methods study design, divided into three distinct phases. In phase 1, outcomes of PE will be identified through a comprehensive systematic review of the literature (phase 1a), followed by exploration of the experiences of individuals who have undergone PE for LARRC and their carers (phase 1b, target sample size 10-20 patients and 5-10 carers). In phase 2, a survey of patients, their carers and clinicians will be conducted using Delphi methodology to explore consensus around the outcomes of highest priority and the level of influence each outcome should have on treatment decision-making. In phase 3 a, risk prediction tool will be developed using data from a single PE referral centre (estimated sample size 500 patients) to predict priority outcomes using multivariate modelling, and externally validated using data from an international PE collaboration. Ethics and dissemination: Ethical approval has been granted for phases 1 and 2 (X22-0422 and 2022/ETH02659) and for maintenance of the database used in phase 3 (X13-0283 and HREC/13/RPAH/504). Informed consent will be obtained from participants in phases 1b and 2; a waiver of consent for secondary use of data in phase 3 will be sought. Study results will be submitted for publication in international and/or national peer reviewed journals.Citation
Brown K, Solomon M, Ng KS, Sutton P, Koh C, White K, et al. Development of a risk prediction tool for patients with locally advanced and recurrent rectal cancer undergoing pelvic exenteration: protocol for a mixed-methods study. BMJ open. 2023 Aug 30;13(8):e075304. PubMed PMID: 37648387. Pubmed Central PMCID: PMC10471871. Epub 2023/08/31. eng.Journal
BMJ OpenDOI
10.1136/bmjopen-2023-075304PubMed ID
37648387Additional Links
https://doi.org/10.1136/bmjopen-2023-075304Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2023-075304
Scopus Count
Collections
Related articles
- Designing and evaluating a patient decision aid for patients with locally advanced or locally recurrent rectal cancer: a national multicentre mixed methods study protocol.
- Authors: Williams A, Hutchings HA, Harris DA, Evans M, Harji D
- Issue date: 2022 Jun 15
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
- Authors: Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P
- Issue date: 2022 Feb 1
- Pelvic exenteration for locally advanced rectal cancer and associated outcomes in England between 1995 and 2016: Analysis of a national database.
- Authors: Rokan Z, Wale A, Day N, Kontovounisios C, Moran B, Brown G
- Issue date: 2024 Oct
- Survival and morbidity outcomes after pelvic exenteration for pelvic sarcoma: an institutional series.
- Authors: Lee PJ, Meshkat B, Sasidharan P, Zahid A, Coker DJ, Solomon MJ
- Issue date: 2022 May
- [Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition)].
- Authors: China PelvEx Collaborative, Colorectal Cancer Committee of the Chinese Medical Doctor Association, Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health Care
- Issue date: 2023 Jan 25